Gilead Announces New Letairis Ambrisentan Data for the Treatment of Patients With Pulmonary Arterial Hypertension WHO Group 1 With WHO Functional Class II or III Symptoms

Gilead Sciences, Inc. (Nasdaq:GILD) announced results of a post-hoc analysis of data collected during the ARIES-1, ARIES-2 and ARIES-E studies for Letairis(R) in pulmonary arterial hypertension (PAH) (WHO Group 1) patients with primarily WHO functional class II or III symptoms. This analysis compared one-year clinical outcomes for PAH (WHO Group 1) patients who initially received placebo during the 12-week, placebo-controlled ARIES-1 and ARIES-2 studies before receiving ambrisentan during a long-term, open-label extension study (ARIES-E) to patients receiving continuous ambrisentan treatment throughout the ARIES studies. Data from this analysis were presented by Vallerie McLaughlin, MD,...

Want to see the full article?

• Purchase this article for only $3.00